Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Gazyvaro 1,000 mg concentrate for solution for infusion., Prograf 1 mg Hartkapseln, Prograf 0,5 mg Hartkapseln, Prograf 5 mg Hartkapseln
Hoffmann-La Roche
Primary Membranous Nephropathy (pMN)
1 trial -
Gefarnate
The First People's Hospital of Lianyungang
Coronary Artery Disease
1 trial -
Gefurulimab
Alexion Europe SAS
Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)
1 trial -
Gemcitabine Eugia 40 mg/ml solution Γ diluer pour perfusion, RILVEGOSTOMIG, Cisplatine Teva 1 mg/ml solution Γ diluer pour perfusion.
CERO THERAPEUTICS HOLDINGS, INC.
Hihg risk of cholangiocarcinoma intra hΓ©patic resectable
1 trial -
General anesthesia and opioids
Elan Pharma International
Breast Neoplasms
1 trial -
Generic Ivermectin Lotion 0.5%
Teva Pharma GmbH
Head Lice
1 trial -
Gilteritinib
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia (AML)
1 trial -
Ginkgo Diterpene Lactone Meglumine Injection
Universal Integrated
Ischemic Stroke
1 trial -
Ginkgo diterpene lactone meglumine injection
Universal Integrated
Ischemic Stroke, Acute
1 trial -
Givinostat 50 mg capsules, RIVAROXABAN , ACETYLSALICYLIC ACID , Givinostat 100 mg capsules, HYDROXYCARBAMIDE, ENOXAPARIN , -, Givinostat 75 mg capsules, DABIGATRAN ETEXILATE
Italfarmaco S.p.A.
JAK2V617F-positive high-risk Polycythemia Vera
1 trial -
Givosiran
Alnylam Netherlands B.V.
Acute Hepatic Porphyria
1 trial -
Glecaprevir/Pibrentasvir
AbbVie
Hepatitis C Virus (HCV)
2 trials -
Glipizide
GlaxoSmithKline
Atherosclerosis
1 trial -
Glycerin Suppository
United Therapeutics Europe Ltd
Encopresis
1 trial -
Gonal-F
The First People's Hospital of Lianyungang
Anovulation
1 trial -
Grafalon 20 mg/ml concentrato per soluzione per infusione
The George Institute
To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.
1 trial -
Gum chewing
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,
Recovery of Bowel Function, Due to Gum Chewing
1 trial -
HD201
Prestige Biopharma Belgium
HER2 Positive Breast Cancer
1 trial -
HEC585
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Idiopathic Pulmonary Fibrosis (IPF)
1 trial -
HEC74647PA+HEC110114
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Chronic HCV Infection
1 trial -
HEPARIN , NADROPARIN
Disc Medicine
All patients who receive ECMO treatment during the study period in one the participating centers from which (deferred) informed consent is obtained. Patients in whom the ECMO is only used to bridge a procedure like a high risk percutaneous coronary intervention or during surgery are excluded.
1 trial -
HETLIOZ 20 mg hard capsules, Placebo will be provided in size and appearance identical to those containing tasimelteon and will be administered orally.
Lacuna Pharma Pty Ltd
Delayed Sleep-Wake Phase Disorder (DSWPD)
1 trial -
HIPEC with neoadjuvant chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Cancer
1 trial -
HLD200 methylphenidate hydrochloride capsules
COLLEGIUM PHARMACEUTICAL, INC
Attention Deficit Hyperactivity Disorder
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources